Walter Strapps
Direktor/Vorstandsmitglied bei SONA NANOTECH INC.
Vermögen: - $ am 30.04.2024
Profil
Walter Strapps is the founder and current Chief Executive Officer of Carver Biosciences, Inc. founded in 2022.
He is also an Independent Director at Sona Nanotech, Inc. since 2022.
Dr. Strapps has held former positions as Director-RNAi Therapeutics at Merck & Co., Inc., Vice President-Discovery Biology at Intellia Therapeutics, Inc., and Chief Scientific Officer at Gemini Therapeutics, Inc. Dr. Strapps has an undergraduate degree from McGill University and a doctorate from Columbia University Vagelos College of Physicians & Surgeons.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SONA NANOTECH, INC.
-.--% | 01.03.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Walter Strapps
| Unternehmen | Position | Beginn |
|---|---|---|
| SONA NANOTECH INC. | Direktor/Vorstandsmitglied | 04.01.2022 |
Carver Biosciences, Inc.
 Carver Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Carver Biosciences, Inc. is a gene therapy company based in Dedham, MA. Carver is developing CRISPR-based therapies for RNA viruses that infect humans, using a programmable platform technology that could offer a generalizable solution for treating many viruses. The company's underlying technology was developed by co-founder Dr. Cameron Myhrvold. Carver Biosciences is leveraging Cas13 to target respiratory viruses at the RNA level, with the aim of destroying the viruses and preventing them from replicating. The company's therapeutics would act in concert with Dr. Uri Lopatin. The company was founded by Cameron Myhrvold and Walter Strapps, with Walter Strapps serving as the CEO since incorporation. | Vorstandsvorsitzender | 01.02.2022 |
Ehemalige bekannte Positionen von Walter Strapps
| Unternehmen | Position | Ende |
|---|---|---|
| GEMI THER | Technik-/Wissenschafts-/F&E-Leiter | 31.12.2021 |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| INTELLIA THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Ausbildung von Walter Strapps
| McGill University | Undergraduate Degree |
| Columbia University Vagelos College of Physicians & Surgeons | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| INTELLIA THERAPEUTICS, INC. | Health Technology |
| MERCK & CO., INC. | Health Technology |
| SONA NANOTECH INC. | Process Industries |
| Private Unternehmen | 2 |
|---|---|
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Carver Biosciences, Inc.
Carver Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Carver Biosciences, Inc. is a gene therapy company based in Dedham, MA. Carver is developing CRISPR-based therapies for RNA viruses that infect humans, using a programmable platform technology that could offer a generalizable solution for treating many viruses. The company's underlying technology was developed by co-founder Dr. Cameron Myhrvold. Carver Biosciences is leveraging Cas13 to target respiratory viruses at the RNA level, with the aim of destroying the viruses and preventing them from replicating. The company's therapeutics would act in concert with Dr. Uri Lopatin. The company was founded by Cameron Myhrvold and Walter Strapps, with Walter Strapps serving as the CEO since incorporation. | Commercial Services |
